City
Epaper

IIT Madras team develops novel database on Covid antibodies

By IANS | Updated: March 20, 2023 13:50 IST

Chennai, March 20 Researchers at the Indian Institute of Technology (IIT) Madras have developed an online open-source database ...

Open in App

Chennai, March 20 Researchers at the Indian Institute of Technology (IIT) Madras have developed an online open-source database of coronaviruses' neutralising antibodies.

The database called 'Ab-CoV' contains detailed information about all Covid-related antibodies identified so far, including the source of each antibody, and the viral protein(s) and virus strains they recognise, the institute said in a statement on Monday.

'Ab-CoV' can also aid in the development of drugs against new variants of SARS-CoV-2.

The Ab-CoV database includes 1,780 coronavirus-related antibodies, including 211 nanobodies, and contains more than 3,200 data points on half maximal inhibitory concentration, half maximal effective concentration and binding affinity.

The information compiled in this database, published in the peer-reviewed journal Bioinformatics, can assist researchers in antibody engineering; analysing immune escape for known and future variants of SARS-CoV-2; computational studies on neutralising antibodies; and relating structural features with binding affinity.

"Some of the data in the Ab-CoV database has already been used to understand the relationship between structural features and binding affinities of spike protein-antibody complexes as well as antibody repurposing," said M. Michael Gromiha, Faculty, Department of Biotechnology, IIT Madras, in the statement.

"Ab-CoV also has a wide range of search and display options through which users can directly search and download the processed data, based on the antibody's name, viral protein epitope, neutralised viral strain, antibody and nanobody. It also has the option to view structures of antibodies or viral proteins in a 3D model," Gromiha added.

Although large amounts of experimental and computational data have been stored online to understand the virus, the emergence of new variants prompted researchers to gather new and comprehensive information.

Such efforts will help to develop newer drugs and deal better with disasters that affect human health and economies, globally.

"AbCoV is an exhaustive repository of antibodies, not just specific to SARS CoV-2 but also to other members of the coronavirus family such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) viruses," said Vani Janakiraman, Faculty, Department of Biotechnology, IIT Madras.

"This repository would aid in comparative studies among different neutralising antibodies across coronaviruses and to assess their properties, interaction patterns with epitopes on the native and mutant viral proteins. Such an effort eventually would help to gauge the efficacy of these antibodies towards existing and emerging viral variants," she added.


rvt/khz/

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Indian Institute Of TechnologyIITVani janakiraman
Open in App

Related Stories

NationalIIT JAM Result 2025 Released at jam2025.iitd.ac.in - Know How to Check

Social ViralMaha Kumbh Mela 2025: Abhay Singh, the Famous IIT Baba, Goes Clean Shaven, New Look Goes Viral

MumbaiIT Powai Fire Incident:: FIR Registered After Suspicious Blaze in Aerospace Department Lab

MumbaiIIT Powai Student Falls Victim to Cyber Fraud: ₹7.29 Lakh Stolen Using Digital Arrest Scam

MumbaiMumbai: IIT Roorkee Team to Inspect Malabar Hill Reservoir; Hanging Garden Group to Present Views

Health Realted Stories

HealthCentre extends financial aid to indigenous indoor air purification solution

HealthChildhood exposure to bacterial toxin can trigger Colorectal cancer among the young: Study

HealthIndia achieves breakthrough in gene therapy for haemophilia: Minister

LifestyleWalking Tips for Summer: Know the Best time to Walk to Avoid Heatstroke

HealthCentre launches campaign to achieve 100 pc Measles-Rubella immunisation coverage